University of North Dakota

UND Scholarly Commons
Physician Assistant Scholarly Project Posters

Department of Physician Studies

2018

Screening Techniques for Alzheimer's Disease
Christina Nicole Brooks
University of North Dakota

Follow this and additional works at: https://commons.und.edu/pas-grad-posters
Part of the Diagnosis Commons, and the Nervous System Diseases Commons
Recommended Citation
Brooks, Christina Nicole, "Screening Techniques for Alzheimer's Disease" (2018). Physician Assistant Scholarly Project Posters. 7.
https://commons.und.edu/pas-grad-posters/7

This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for
inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please
contact zeineb.yousif@library.und.edu.

Screening Techniques for Alzheimer’s Disease
Christina Brooks, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract
Alzheimer’s disease is a neurodegenerative disease that
affects more than 55 million Americans. By the year 2050,
experts project this disease will have increased three fold.
Many screening techniques have been investigated to detect
this disease early and begin treatment to slow its progression.
The purpose of this study was to explore which medical
modalities are the most effective for screening of Alzheimer’s
disease. This literature review includes three databases,
including PubMed, CINHAL, and Cochrane Database of
Systematic Reviews. Topics that were researched include:
cognitive screening tests, neuroimaging, laboratory diagnostic
testing, DNA, and combined studies. All resources were
published within the last ten years. Limitations and strengths
were considered within each modality. In each category, the
following were found to be the most effective in screening for
Alzheimer’s disease: cognitive screening tests: MOST and
MoCA testing; neuroimaging: PET scanning; laboratory
diagnostic testing: biomarkers; DNA: DNA methylation and
APOE genotyping; and combined studies: PET scanning. This
review demonstrates that there are many screening
modalities available to providers. This allows providers to
choose their screening technique based on their site’s
availability, provider preference, and cost.

Introduction
• Alzheimer’s disease is defined as a chronic neurodegenerative
disorder that is seen primarily in adults who are older than 65
• Currently, there is no cure for Alzheimer’s disease and current
treatment options have many side effects. The hope with early
detection is to give patients a better quality of life with the
initiation of early treatment.
• With each research analysis, the research’s strengths,
weaknesses, and findings was compiled into meaningful
conclusions
• This research will enable clinicians and medical facilities to be
well versed in the various screening techniques available and
be able to provide better care to their patients

Statement of the Problem
• A key issue with researching Alzheimer’s disease is its difficulty
to diagnose
• Without fulling understanding the disease, how can practitioners
provide effective care and treatment?
• To date, there is no known screening test that has been shown
to detect this disease with 100% accuracy

Research Questions
• What are the most effective screening options in the detection of
Alzheimer’s disease?
• What limitations exist in these screening techniques?
• What are the benefits in the different screening techniques?

Literature Review

Applicability to Clinical
Practice

Cognitive Screening Test
• Clinosky and Clinosky (2010) investigated whether integration of
3-word recall, list memory, clock drawing, and time orientation
into the Memory Orientation Screening Tests (MOST) would be a
more accurate means of screening for Alzheimer’s disease
compared to Mini-Cog screening test and the Mini-Mental State
Examination (MMSE)
• Freitas, Simoes, Alves, and Santana (2013) conducted a study
to determine whether the Montreal Cognitive Assessment
(MoCA) or the MMSE, was a better screening tool for cognitive
decline
• Nakashima et al. (2015) designed a study to find if there is a
correlation between regional cerebral blood flow and types of
errors on the Clock Drawing Test in Alzheimer’s patients
Neuroimaging
• Fu et al. (2014) compared the (18) F-FDG PET scanner and the
“dual biomarker” (11) C-PIB PET [(11) C-pPIB and amyloid PIB
((11) C-aPIB)] for a screening of Alzheimer’s disease, patients
with mild cognitive impairment, and patients that were cognitively
“normal”
• Rabinovici et al. (2011) compared PET scanning with amyloid
ligand Pittsburgh compound B (PiB-PET) to flouorodeoxyglucose
(FDG-PET) in discriminating between frontotemporal lobar
degeneration and Alzheimer disease
• Smailagic et al. (2015) investigated different studies regarding
the accuracy of the F-FDG PET scan in identification of patients
with mild cognitive impairment who would progress to
Alzheimer’s dementia or other types of dementia
Laboratory Diagnostic Testing
• Burnham et al. (2016) investigated whether high or low
neocortical beta-amyloid proteins (NAB) could predict a patient’s
risk of development of Alzheimer’s disease within a 54-month
period
• Mattsson et al. (2016) designed a study to test whether there is a
correlation between plasma tau and Alzheimer’s disease
• O’Bryant et al. (2011) designed a study to investigate the
relationship between serum biomarker proteins and Alzheimer’s
disease
• Vemuri et al. (2017) identified 430 patients (age greater than 60)
that were from the Mayo Clinic Study of Aging. Researchers
wanted to investigate whether there is a correlation between
patients with comorbidities and neurodegeneration
DNA
• Bollati et al. (2011) explored whether there is a relationship
between DNA methylation and Alzheimer’s disease
• Kennedy, Cutter, and Schneider (2014) tested the apolipoprotein
E epsilon4 genotype as a means of inclusion or exclusion in
clinical trials for Alzheimer’s disease
Combined Studies
• Bateman et al. (2012) performed a longitudinal study
investigating beta-amyloid CSF, PET scanning, tau proteins in
CSF, and MMSE as a means for screening of Alzheimer’s
disease
• Palmqvist et al. (2015) compared the accuracy of CSF
biomarkers to amyloid PET scanning in diagnosing early-stage
Alzheimer’s disease

• This research proves that there are different medical modalities
that can be used for screening of Alzheimer’s disease both in
rural and urban communities
• Each screening test varies in the time it takes undergo the
study, and the time it takes to obtain results
– Cognitive screening tests would be considered the fastest of
the screening techniques discussed
• Clinicians should be well-versed on the screening techniques
that they have available, and be able to interrupt the results
• With early detection of this disease, implementation of
treatments can begin and slow the disease progression
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